Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion

Retina

Volumn 33, Issue 1, 2013, Pages 56-62

  Spaide, Richard ^a,b  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN;

ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; LASER COAGULATION; MACULAR THICKNESS; OPHTHALMOLOGY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PANRETINAL PHOTOCOAGULATION; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FLUORESCEIN ANGIOGRAPHY; HUMANS; LASER COAGULATION; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84872071656     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182641875     Document Type: Article

References (36)

1. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-1645.
2. Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 2011. Epub ahead of print.
3. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:270-271.
4. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
5. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144:864-871.
6. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
7. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16: 791-799.
8. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion - results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429-1436.
9. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007;27: 1004-1012.
10. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007; 27:1013-1019.
11. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 2008;116:147-152.
12. Pournaras JA, Nguyen C, Vaudaux JD, et al. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results. Klin Monbl Augenheilkd 2008;225:397-400.
13. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115: e47-e54.
14. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
15. Rouvas A, Petrou P, Vergados I, et al. Intravitreal ranibizumab (lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol 2009;247: 1609-1616.
16. Chang LK, Spaide RF, Klancnik JM, et al. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina 2011;31:821-828.
17. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010;150:310-314.
18. Pece A, Isola V, Piermarocchi S, Calori G. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 2011;95:56-68.
19. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-2049.
20. Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, et al. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci 2011;52:3334-3337.
21. Risard SM, Pieramici DJ, Rabena MD, et al. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion. Retina 2011;31:1060-1067.
22. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983;90:458-474.
23. Hayreh SS, Klugman MR, Beri M, et al. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol 1990;228:201-217.
24. Clarkson JG. Central vein occlusion study group: photographic protocol and early natural history. Trans Am Ophthalmol Soc 1994;92:203-215.
25. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The CVOS Group N Report. Ophthalmol 1995;102:1434-1444.
26. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486-491.
27. Spaide RF. Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography. Retina 2011;31:829-837.
28. Prasad PS, Oliver SC, Coffee RE, et al. Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology 2010;117:780-784.
29. Tsui I, Kaines A, Havunjian MA, et al. Ischemic index and neovascularization in central retinal vein occlusion. Retina 2011;31:105-110.
30. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina 1981;1:27-55.
31. Hayreh SS, Rojas P, Podhajsky P, et al. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983;90:488-506.
32. Shinoda K, Ishida S, Kawashima S, et al. Clinical factors related to the aqueous levels of vascular endothelial growthfactor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res 2000;21:655-661.
33. Gaucher D, Fortunato P, LeCleire-Collet A, et al. Spontaneous resolution of macular edema after panretinal photocoagulation in florid proliferative diabetic retinopathy. Retina 2009;29: 1282-1288.
34. Shimura M, Yasuda K, Nakazawa T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:1617-1624.
35. Goldenberg-Cohen N, Dadon S, Avraham BC, et al. Molecular and histological changes following central retinal artery occlusion in a mouse model. Exp Eye Res 2008;87: 327-333.
36. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993;3:244-250.